DK0593516T3 - Fremgangsmåder til behandling af motorneuronsygdomme ved anvendelse af medlemmer af BDNF/NT-3/NGF-molekylfamilien - Google Patents

Fremgangsmåder til behandling af motorneuronsygdomme ved anvendelse af medlemmer af BDNF/NT-3/NGF-molekylfamilien

Info

Publication number
DK0593516T3
DK0593516T3 DK92912453T DK92912453T DK0593516T3 DK 0593516 T3 DK0593516 T3 DK 0593516T3 DK 92912453 T DK92912453 T DK 92912453T DK 92912453 T DK92912453 T DK 92912453T DK 0593516 T3 DK0593516 T3 DK 0593516T3
Authority
DK
Denmark
Prior art keywords
bdnf
motor neuron
members
methods
neuron diseases
Prior art date
Application number
DK92912453T
Other languages
English (en)
Inventor
Vivien Wong
Czeslaw Radziejewski
Peter Distefano
Original Assignee
Regeneron Pharma
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Max Planck Gesellschaft filed Critical Regeneron Pharma
Application granted granted Critical
Publication of DK0593516T3 publication Critical patent/DK0593516T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Physical Water Treatments (AREA)
  • Water Treatment By Electricity Or Magnetism (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Water Treatment By Sorption (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK92912453T 1991-07-10 1992-05-19 Fremgangsmåder til behandling af motorneuronsygdomme ved anvendelse af medlemmer af BDNF/NT-3/NGF-molekylfamilien DK0593516T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72770491A 1991-07-10 1991-07-10
PCT/US1992/004228 WO1993001300A1 (en) 1991-07-10 1992-05-19 Methods of treatment of motor neuron diseases using members of the bdnf/nt-3/ngf family of molecules

Publications (1)

Publication Number Publication Date
DK0593516T3 true DK0593516T3 (da) 2001-09-17

Family

ID=24923677

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92912453T DK0593516T3 (da) 1991-07-10 1992-05-19 Fremgangsmåder til behandling af motorneuronsygdomme ved anvendelse af medlemmer af BDNF/NT-3/NGF-molekylfamilien

Country Status (20)

Country Link
EP (2) EP0755682A1 (da)
JP (1) JPH06509094A (da)
CN (1) CN1065768C (da)
AT (1) ATE202939T1 (da)
AU (2) AU675409B2 (da)
CA (1) CA2113083A1 (da)
DE (1) DE69231930T2 (da)
DK (1) DK0593516T3 (da)
ES (1) ES2157903T3 (da)
FI (1) FI940098A7 (da)
GR (1) GR3036776T3 (da)
HU (1) HUT70275A (da)
IE (1) IE921602A1 (da)
IL (1) IL101928A0 (da)
NO (1) NO940084L (da)
PT (1) PT100501A (da)
RU (1) RU94016525A (da)
SK (1) SK2694A3 (da)
WO (1) WO1993001300A1 (da)
ZA (1) ZA923639B (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0644937A4 (en) * 1992-06-12 1995-05-03 Regeneron Pharmaceuticals, Inc. Therapeutic and diagnostic methods based on neurotrophin-4 expression.
FR2717496B1 (fr) * 1994-03-18 1996-04-12 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
CN1112215C (zh) * 1999-12-28 2003-06-25 潘晓东 神经生长因子在治疗有机溶剂中毒性周围神经病中的用途
DE60137414D1 (de) 2000-05-05 2009-03-05 Univ City Zusammensetzungen zur stimulierung der regeneration und der wiederherstellung des nervensystems durch regulierung der arginase 1- und polyamin-synthese
WO2008156418A1 (en) * 2007-06-19 2008-12-24 Astrazeneca Ab A method for screening or diagnosis of postpolio syndrome and fibromyalgia
PL2187964T3 (pl) * 2007-08-10 2015-03-31 Regeneron Pharma Ludzkie przeciwciała o wysokim powinowactwie przeciw ludzkiemu czynnikowi wzrostu nerwu
WO2014111525A2 (en) 2013-01-18 2014-07-24 Anaxomics Biotech, Sl New combination therapies for treating nervous system diseases
US10349890B2 (en) 2015-06-26 2019-07-16 C. R. Bard, Inc. Connector interface for ECG-based catheter positioning system
US20250170212A1 (en) * 2022-02-28 2025-05-29 Bioincept, Llc Compositions and methods of treating amyotrophic lateral sclerosis (als) and related disorders
GB202303495D0 (en) * 2023-03-09 2023-04-26 Ucl Business Ltd Therapy for charcot-marie-tooth disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923696A (en) * 1987-05-04 1990-05-08 Baylor College Of Medicine Method to prepare a neurotrophic composition
IL95511A (en) * 1989-08-30 2000-10-31 Max Planck Gesellschaft Neurotrophin-3 a novel neurotrophic factor related to nerve growth and brain derived neurotrophic factor
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
IE903130A1 (en) * 1989-09-15 1991-03-27 Regeneron Pharma Ciliary neurotrophic factor

Also Published As

Publication number Publication date
FI940098A0 (fi) 1994-01-10
RU94016525A (ru) 1996-06-10
SK2694A3 (en) 1995-02-08
ZA923639B (en) 1993-02-24
WO1993001300A1 (en) 1993-01-21
CN1071585A (zh) 1993-05-05
JPH06509094A (ja) 1994-10-13
HU9400063D0 (en) 1994-06-28
IE921602A1 (en) 1993-01-13
FI940098A7 (fi) 1994-03-10
NO940084D0 (no) 1994-01-10
HUT70275A (en) 1995-09-28
DE69231930T2 (de) 2002-04-11
EP0593516A1 (en) 1994-04-27
CA2113083A1 (en) 1993-01-21
AU2009592A (en) 1993-02-11
ES2157903T3 (es) 2001-09-01
ATE202939T1 (de) 2001-07-15
IL101928A0 (en) 1992-12-30
PT100501A (pt) 1993-09-30
DE69231930D1 (de) 2001-08-16
EP0593516B1 (en) 2001-07-11
GR3036776T3 (en) 2002-01-31
AU7067696A (en) 1997-01-16
EP0593516A4 (en) 1995-01-18
AU675409B2 (en) 1997-02-06
EP0755682A1 (en) 1997-01-29
CN1065768C (zh) 2001-05-16
NO940084L (no) 1994-03-08

Similar Documents

Publication Publication Date Title
FI108146B (fi) Biologisesti aktiivisten, neurotrofisten NGF/BDNF-sarjan yhdistelmäproteiinien valmistus
NO951592L (no) Fremgangsmåte for fremstilling av et transdermalt terapeutisk system
DE3880766D1 (de) Konjugate von interferon alpha mit immunglobulinen.
NO940084D0 (no) Fremgangsmaate for behandling av motor-neuron sykdommer ved anvend else av medlemmer av BDNF/NT-3/NGF familien av molekyler
ATE545429T1 (de) Modulation der neurotrophinaktivität;screeningsverfahren
ATE213411T1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
DE69203254D1 (de) Herstellung von Crackkatalysatoren und Crackverfahren mit diesen.
ATE199167T1 (de) Nichtglykosyliertes fgf-4 und dieses enthaltende präparate
DE3786528D1 (de) Fluorharz enthaltende beschichtungszusammensetzung und diese verwendende fixierheizwalze.
NO882853L (no) Korreksjon med dobbeltraadet rna av unormale tilstander i immunkomplekser som er i omloep, og i monocyttfunkjon.
PT86346A (en) Method of treatment by means of the 3:-deoxitimidinene-2:(3:deoxi-2:3:-didesidrotimidine) administration to animals of hot blood infected with retrovirus
DE3782346D1 (de) Verwendung von chinolon und naphthyridin-antibiotika zur herstellung von ophthalmischen arzneimitteln.
EP0295280A4 (en) Use of protoporphyrin and stannic mesoporphyrin for the manufacture of a medicament for the treatment of psoriasis.
DK36889A (da) Anvendelse af et benzamidderivat til fremstilling af et middel til behandling eller forebyggelse af kognitive lidelser
AU7426487A (en) Method of treating depression using d-fenfluramine
FI891475A0 (fi) Foerfarande foer framstaellning av natriumfluoralkoholat.
DK0538690T3 (da) Arylquinolyl-substituerede 1,4-dihydropyridin-dicarboxylsyrederivater, fremgangsmåde til deres fremstilling af deres anvendelse i lægemidler
Aurela A systematic storytelling therapy.
DK0868914T3 (da) Farmaceutisk præparat til bekæmpelse og behandling af ano-rektal- og colon-sygdomme
DE19739761A1 (de) Verwendung von Ozon und zusätzlich noch dosierte Vitamin E Indikation zur Blutbehandlung
RU96117545A (ru) Способ лечения диабетической ретинопатии
Hoogduin et al. Double-Blind Research Psychotherapy
RU93008692A (ru) Способ рефлексотерапии
UA12628A (uk) Спосіб лікуваhhя гострого вірусhого гепатиту
RU93037460A (ru) Способ лечения псориаза и пузырчатки